Objective: To characterize the primary structure of the active national standard candidate of infliximab to provide a technical basis for this monoclonal antibody. Methods: The complete relative molecular mass and the relative molecular masses of the light and heavy chain subunits of the active national standard candidate of infliximab were detected based on ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS). The relative molecular masses of the light and heavy chain subunits of the active national standard candidate of infliximab were analyzed by UPLC-MS/MS. UPLC-MS/MS was used to analyze the sequence coverage, glycosylation sites and disulfide bond localization of infliximab activity candidate national standard products. Results: The complete relative molecular mass of infliximab was 148 515. The relative masses of its light and heavy chain subunits were 23 435 and 50 827 respectively. The sequence coverage of infliximab was 100% for light chain and 100% for heavy chain. The glycosylation sites of infliximab were analyzed by UPLC-MS/MS; and the disulfide bonds were localized. The glycosylation site of the monoclonal antibody candidate was located at N300 of the heavy chain; there were 16 pairs of disulfide bonds, 4 pairs within each of the two heavy chains, 2 pairs between chains, 2 pairs within each of the 2 light chains, and 1 pair between each of the two groups of light and heavy chains. Conclusion: The primary structural confirmation of the national standard candidate of infliximab monoclonal antibody activity provides a technical guarantee for the establishment of the monoclonal antibody standard substance, the standardization of analytical methods and the control of product quality.
LI Wei-yu
,
ZHANG Jia-ling
,
LI Meng
,
YU Xiao-juan
,
WU Gang
,
YU Chuan-Fei
,
WANG Lan
. Primary structure characterization of the active national standard candidate of infliximab*[J]. Chinese Journal of Pharmaceutical Analysis, 2025
, 45(3)
: 460
-474
.
DOI: 10.16155/j.0254-1793.2024-1266
[1] 付志浩,徐刚领,黄璟,等.单克隆抗体药物研发进展[J].中国药事,2021,35(11):1253
FU ZH,XU GL,HUANG J,et al.Advances in the development of monoclonal antibody drugs[J].China Pharm Aff,2021,35(11):1253
[2] 陈宁,唐婧,李锦,等.单克隆抗体药物的研究现状和热点分析[J].中国医院用药评价与分析,2023,23(1):116
CHEN N,TANG J,LI J,et al.Analysis of the research status and hot spots for monoclonal antibody drugs[J].Eval Anal Drug Use Hosp China,2023,23(1):116
[3] 杨翼.中国药王PK世界药王「销售额TOP榜」[Z/OL].(2024-05-25) [2024-08-20].https://mp.weixin.qq.com/s/tpx_AbgqqIlg SoPCbue5bQ
YANG J.China’s King of Pharmaceuticals PK World’s King of Pharmaceuticals「Sales TOP List」[Z/OL].(2024-05-25)[2024-08-20].https://mp.weixin.qq.com/s/tpx_AbgqqIlgSoPCbue5bQ
[4] FOBELO LOZANO MJ,SERRANO GIMENEZ R,SANCHEZ FIDALGO S.Therapeutic drug monitoring of infliximab in spondyloarthritis.A review of the literature[J].British Journal of Clinical Pharmacology,2019,85(10):2264
[5] 耿庆迪. 英夫利西单抗与托珠单抗治疗中重度类风湿关节炎的疗效与安全性分析[D].济南:山东大学,2023
GENG QD.Efficacy and Safety Analysis of Infliximab and Tolizumab in the Treatment of Moderate to Severe Rheumatoid Rthritis[D].Jinan:Shandong University,2023
[6] JANG D,LEE AH,SHIN HY,et al.The role of tumor necrosis factor alpha(TNF-α)in autoimmune disease and current TNF-α inhibitors in therapeutics[J].INT J MOL SCI,2021,22(5):2719
[7] 刘春雨,于传飞,武刚,等.英夫利西单抗质量控制中的趋势分析[J].药物分析杂志,2019,39(1):30
LIU CY,YU CF,WU G,et al.Trend analysis in quality control of Infliximab[J].Chin J Pharm Anal,2019,39(1):30
[8] ABOOBACKER S,AL ABOUD AM.Infliximab-abda[M].Treasure Island(FL):StatPearls Publishing,2023
[9] 赵雪羽,李萌,武刚,等.以CD79b为靶点的抗体偶联药物的一级结构表征[J].中国药学杂志,2023,58(1):33
ZHAO XY,LI M,WU G,et al.Primary structure characterisation of antibody-coupled drugs targeting CD79b[J].Chin Pharm J,2023,58(1):33
[10] 朱文文,李梦林,张金兰.单克隆抗体药物质量分析质谱技术研究进展[J].药学学报,2020,55(12):2843
ZHU WW,LI ML,ZHANG JL.Advances in mass spectrometry for quality analysis of monoclonal antibody drugs[J].Acta Pharm Sin,2020,55(12):2843
[11] 周培,沈玉婷,沈卫东.英夫利西单抗治疗克罗恩病的疗效及安全性分析[J].系统医学,2023,8(3):119
ZHOU P,SHEN YT,SHEN WD.Efficacy and safety analysis of Infliximab in the treatment of Crohn’s disease[J].Syst Med,2023,8(3):119
[12] SMOLEN JS,EMERY P.Infliximab:12 years of experience[J].Arthritis Res Ther,2011,13:1
[13] WHO.Recommendations for the Preparation,Characterization and Establishment of International and Other Biological Reference standards[EB/OL].(2006-10-20)[2022-06-13].https://www.who.int/publications/m/item/annex-2-trs-no-932
[14] WHO.WHO Expert Committee on Biological Standardization:Seventy-ninth Report.Geneva:World Health Organization[EO/OL].(2024-08-05)[2024-10-20].https://www.who.int/publications/i/item/9789240097971
[15] 李佳婧,温学美,刘菊,等.LC-MS/MS在线部分还原法快速表征雷珠单抗一级结构[J].中国医药工业杂志,2023,54(11):1624
LI JJ,WEN XM,LIU J,et al.Rapid characterisation of the primary structure of ranibizumab by LC-MS/MS on-line partial reduction[J].Chin J Pharm,2023,54(11):1624
[16] 曹丽梅,刘明理,袁伟媛,等.国家药品标准物质在生物制品质量控制中的应用[J].中国生物制品学杂志,2019,32(9):1054
CAO LM,LIU ML,YUAN WY,et al.Application of national drug standard substances in quality control of biological products[J].Chin J Biol,2019,32(9):1054
[17] 徐梦娇,刘涛,徐进,等.英夫利西单抗糖化方法开发验证及其在抗体药物中的普适性[J].聊城大学学报(自然科学版),2024,37(5):155
XU MJ,LIU T,XU J,et al.Validation of Infliximab glycation method development and its generalisation to antibody drugs[J].J Liaocheng Univ(Nat Sci Ed),2024,37(5):155
[18] 王福贵,刘涛,李锦豪,等.多糖基化位点抗体药物质控中基于单四级杆的多属性分析方法开发与验证[J].聊城大学学报(自然科学版),2024,37(5):169
WANG FG,LIU T,LI JH,et al.Development and validation of a single quadrupole-based multi-attribute analysis method for quality control of antibody drugs with multiple glycosylation sites[J].J Liaocheng Univ(Nat Sci Ed),2024,37(5):169
[19] XU MJ,LIU T,XU J,et al.Rapid mass spectrometry-based multiattribute method for glycation analysis with integrated afucosylation detection capability[J].J Am Soc Mass Spectrom,2024,35(8):1669
[20] 朱文文. 基于质谱技术曲妥珠单抗等三种药物结构表征与杂质分析新方法研究[D].北京:中国医学科学院,2021
ZHU WW.A New Method for Structural Characterisation and Impurity Analysis of Trastuzumab and Three Other Drugs based on Mass Spectrometry[D].Beijing:Chinese Academy of Medical Sciences,2021
[21] NIBSC.WHO International Standard 1st International Standard for Infliximab 16/170[EB/OL].(2019-01-15)[2024-10-23].https://nibsc.org/products/brm_product_catalogue/detail_page.aspx?catid=16/170
[22] EDQM.Information Leaflet Ph.Eur.Reference Standard Infliximab BRP batch1[EB/OL].(2021-10-04)[2024-10-23].https://crs.edqm.eu/db/4DCGI/search?vSelectName=1&vContains=1&vtUserName=Infliximab&OK=Search&vTypeCRS=
[23] 王一平,梁争论,毛群颖.WHO国际疫苗标准物质和中国国家疫苗标准物质的研究进展[J].微生物学免疫学进展,2024,52(3):71
WANG YP,LIANG ZL,MAO QY.Research progress of WHO international vaccine standard material and Chinese national vaccine standard material[J].Prog Microbiol Immunol,2024,52(3):71
